Bak gene encodes a 23kDa-protein homologue of apoptosis inhibitor Bcl-2. Unlike Bcl-2, Bak stimulates several apoptosis pathways, and by interacting with Bcl-2 or Bcl-x L , it counteracts the anti-cell death effect. Enforced expression of Bak induces rapid and extensive apoptosis of serumdeprived fibroblasts. In contrast, the mutation of the Bak gene was observed in several cancer cells, suggesting a deficiency of the Bak cellular function can cause a cancerous malignancy. Although many studies of Bak have been performed, the mechanisms by which Bak functions in mammalian cells remain unclear. In this study, we constructed a hammerhead ribozyme specifically targeted to the Bak mRNA for inhibition of the intracellular function of Bak. This Bak-ribozyme should be useful for a detailed functional analysis of Bak.
INTRODUCTION
Programmed cell death (apoptosis) is an essential and complex process, balancing an animal's cell numbers in both development and in adult homeostasis (1). The Bcl-2 family proteins play central roles in the regulation of this process, which is induced by a wide variety of stimuli such as serum deprivation, FAS antigen, and TNF-a (2) . Several members of the Bcl-2 family of proteins physically interact via specific conserved domains, forming both homo-and heterodimers. In previous studies of Bcl-2 family proteins, both Bcl-2 and Bcl-x L have functioned to prevent cell death, whereas Bax, Bad, Bit and Bak appear to have accelerated cell death signals (3, 4) .
In a pro-apoptotic member, Bak (a Bcl-2 homologue antagonist/killer) has been cloned as a gene encoding E1B19K binding protein, which is known to inhibit apoptosis (5) . Thus, it is suggested that the E1B19K protein inhibits apoptosis, at least in part, by binding to Bak and inhibiting its pro-apoptotic function (6) . Recent studies have revealed that overexpression of Bak mediates the killing of cancer cells (7) . Although many studies of Bak have been performed, the molecular basis of Bak functions in mammalian cells remains unclear.
In this study, we constructed a Bak-specific hammerhead ribozyme and, for the investigation of a molecular basis for the pro-apoptotic Bak functions, tried a knock-down of Bak expression in mammalian cells.
RESULTS AND DISCUSSION
To have a better understanding of the molecular basis of Bak's cellular function, two kinds of hammerhead ribozyme specifically targeted to the Bak mRNA (Bakribozyme) were constructed. Hammerhead ribozymes are catalytic RNA molecules that bind to specific RNA target molecules based on sequence complementarity, and enzymatically cleave their RNA targets. This cleavage requires a NUX triplet in the RNA target sequence (N: A,U,G or C ; X: A, U or C). By meeting this requirement, any RNA targets could potentially be cleaved (8, 9) . First, target sites on Bak mRNA where the ribozyme cleaves were selected. The selection was carried out following three criteria. 1: A NUX triplet exists in the target sequence. 2: The target site and its flanking region do not form a duplex. 3: Bak-ribozymes form expected conformations by avoiding duplex formation recognition arms of the ribozyme (see Fig.) . A prediction of the secondary structure of these RNA conformations was calculated using the Mfold program (10) . Next, to construct the Bak-ribozyme expression vector, we used a plasmid vector carrying a human tRNA Val promoter. This RNA pol III dependent expression system is suitable for short RNAs, and the level of expression is at least 10 to 100-fold higher than that of the pol II dependent system (11) . In this pol III system, the two Bakribozymes were fused to the 3' region of the tRNA Val sequence (see Figure) . The plasmids that contained the Bak-ribozyme were transfected into MCF-7 cells (a human breast carcinoma caspase-3 defective cell line). To obtain cells that stably expressed the Bak-ribozyme, cells were treated with a puromycin-containing medium for 4 weeks. The expression of Bak-ribozymes was then confirmed using a RT-PCR analysis.
To examine the level of Bak mRNA in Bak-ribozyme expressing cells, RT-PCR analysis was again performed. In comparison with normal cells, the level of Bak mRNA was partially reduced in MCF-7 cells that stably expressed the Bak-ribozyme. On the other hand, no differences were found in the expression levels of (3-Actin and DHFR mRNA between Bakribozyme expressing and normal cells.
Next, MCF-7 cells that stably expressed Bakribozyme were subjected to a TNF-a-induced apoptosis assay to check Bak functions in TNF-ainduced apoptosis pathway. As a result, the rate of cell survival of Bak-ribozyme, especially #2, expressing cells was partially increased compared with that of wild type MCF-7 cells. Therefore, it follows that Bak might, at least partially, participate in the TNF-cc-mediated apoptosis in MCF-7 cells. Indeed, Bak was identified using a gene discovery system with randomized ribozyme libraries in the apoptosis pathway (Kawasaki and Taira, unpublished data). For the detection of partial, but not drastic differences in this assay we suggest three reasons. 1. Apoptosis is a complex pathway composed of so many factors and signaling pathways. Thus, defection of Bak doesn't confer any drastic affect on the apoptosis pathway. 2. Reduction of Bak expression by the ribozyme is partial. A drastic reduction may have revealed the function of Bak. 3. Bak does not function as an apoptotic factor. However, as there are so many studies regarding the pro-apoptotic Bak functions, this final reason is improbable, leaving just reasons 1 and 2 seem as probabilities. The Bak-ribozyme will be used for further investigations to reveal pro-apoptotic function of Bak.
